Cytokinetics Inc at JPMorgan Healthcare Conference Transcript

Jan 08, 2024 / 03:30PM GMT
Tessa Romero J.P. Morgan-Analyst

Welcome everyone to the 42nd Annual JPMorgan Healthcare Conference. My name is Tessa Romero, and I am one of the senior biotech analysts here at JPMorgan. I'm pleased to welcome Cytokinetics as our first presenting company at the conference. And speaking on behalf of the Company, we have CEO, Robert Blum. Robert, over to you.

Robert Blum Cytokinetics Inc-President&CEO

Thank you and thank you for allowing Cytokinetics to present here an update on recent activities and are forward looking statements and forward-looking views to the company in 2024, I will be making some forward-looking statements, so I refer you to our SEC filings with regard to caveats to those statements, and we don't undertake any obligation to update with regard to those statements.

So as you may know, Cytokinetics has been on a mission on a mission for now over 25 years to discover and develop new medicines that read on muscle biology and in particular relate to health span of people suffering from devastated

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
4.6 out of 5 Trustpilot